SAN FRANCISCO, March 2, 2016 /PRNewswire/ -- Trianni, Inc. (TRIANNI) announces that key aspects of its human antibody mouse platform were issued a patent by the Federal Service for Intellectual Property (ROSPATENT), Ministry of Economic Development of the Russian Federation.
The ROSPATENT allowance covers a transgenic mouse with an engineered endogenous immunoglobulin locus deleted of its variable region gene segments and instead containing arrays of chimeric immunoglobulin gene segments. The chimeric gene segments consist of human immunoglobulin coding sequences and non-coding sequences based on the mouse immunoglobulin variable region locus. They thus confer the capacity to express antibody chains with human variable regions. The patent also covers the methods for generating the mouse.
"We are pleased with the addition of the Russian patent to our patent portfolio," commented Dr. Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. "This addition further strengthens TRIANNI's position in monoclonal antibody discovery platform."
About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.
Zishan Haroon, MD, PhD
Chief Business Officer
Director of Marketing
SOURCE Trianni, Inc.